


55-215 GP/1803



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Our Ref: 1887-111 MIS:as

In patent application

No. 08/307,621  
Applicant: K.N. Dolynchuck et al  
Title: USE OF TRANSGLUTAMINASE INHIBITOR FOR THE TREATMENT OF SCAR TISSUE  
Filed: March 23/92  
Group No. 1803  
Examiner: R. Griffin

#  
7/B  
KD  
3-26-96

January 31, 1996

96FEB29 PM 6:02  
GROUP: 120

AMENDMENT

BY COURIER

The Commissioner of Patents  
and Trademarks,  
Washington, D.C. 20231,  
U.S.A.

Dear Sir:

In response to the Office Action of October 16,  
1995, please amend this application in the following manner:

In the Claims:

Amend claims 8 and 11 as follows:

8. (Amended) A method of treating or preventing hypertrophic scar tissue in humans, comprising applying to extracellular wound [the] scar tissue in human skin an effective amount of a non-toxic amine compound [transglutaminase inhibitor] having a free amino group, said amine compound being a transglutaminase inhibitor which is selective for inhibiting Type III collagen isopeptide cross-linking, or a pharmaceutically-acceptable acid addition salt of said amine compound, [thereof] in the form of a composition with [, and] a pharmaceutically-acceptable carrier or diluent and formulated for topical application to said extracellular wound.

11. (Amended) A method according to claim 8 [10] wherein the amine compound [inhibitor] is a primary amine.

(Add new claim 16 as follows:)

16. (New) The method of claim 8 including the further step of occluding the wound with a dressing.